Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Chengyong Tang

Showing results (21-30 of 27) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 27 results.
Scientific Reports|October 21, 2024
Study on bioequivalence and influence of obesity-related indicators on pharmacokinetics and pharmacodynamics for insulin degludec in healthy subjectsRui Su, Lei Wan, Yi Tao, et al.
Oncotarget|July 10, 2015
MiR-101 targets DUSP1 to regulate the TGF-β secretion in sorafenib inhibits macrophage-induced growth of hepatocarcinomaXufu Wei, Chengyong Tang, Xiuxian Lu, et al.
Diabetes, Obesity & Metabolism|July 15, 2025
First-in-human study of HDM1002, a GLP-1 receptor agonist: Safety, tolerability, pharmacokinetics and pharmacodynamics of escalating single oral doses in healthy volunteersJunliang Pu, Yurui Huang, Lei Wan, et al.
Oncotarget|November 12, 2016
IL-37 suppresses hepatocellular carcinoma growth by converting pSmad3 signaling from JNK/pSmad3L/c-Myc oncogenic signaling to pSmad3C/P21 tumor-suppressive signalingRui Liu, Chengyong Tang, Ai Shen, et al.
Journal of Clinical Gastroenterology|October 9, 2013
A systematic review of sorafenib in Child-Pugh A patients with unresectable hepatocellular carcinomaAi Shen, Chengyong Tang, Yefei Wang, et al.
Diabetes, Obesity & Metabolism|February 12, 2025
Safety, tolerability, pharmacokinetics and pharmacodynamics of GZR4, a novel once-weekly basal insulin, in healthy participants: A randomized trialChengyong Tang, Rui Su, Lei Wan, et al.
Eclinicalmedicine|May 30, 2023
Artificial intelligence-assisted ultrasound image analysis to discriminate early breast cancer in Chinese population: a retrospective, multicentre, cohort studyJianwei Liao, Yu Gui, Zhilin Li, et al.
Pageof 3

Showing results (21-30 of 27) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 27 results.
Scientific Reports|October 21, 2024
Study on bioequivalence and influence of obesity-related indicators on pharmacokinetics and pharmacodynamics for insulin degludec in healthy subjectsRui Su, Lei Wan, Yi Tao, et al.
Oncotarget|July 10, 2015
MiR-101 targets DUSP1 to regulate the TGF-β secretion in sorafenib inhibits macrophage-induced growth of hepatocarcinomaXufu Wei, Chengyong Tang, Xiuxian Lu, et al.
Diabetes, Obesity & Metabolism|July 15, 2025
First-in-human study of HDM1002, a GLP-1 receptor agonist: Safety, tolerability, pharmacokinetics and pharmacodynamics of escalating single oral doses in healthy volunteersJunliang Pu, Yurui Huang, Lei Wan, et al.
Oncotarget|November 12, 2016
IL-37 suppresses hepatocellular carcinoma growth by converting pSmad3 signaling from JNK/pSmad3L/c-Myc oncogenic signaling to pSmad3C/P21 tumor-suppressive signalingRui Liu, Chengyong Tang, Ai Shen, et al.
Journal of Clinical Gastroenterology|October 9, 2013
A systematic review of sorafenib in Child-Pugh A patients with unresectable hepatocellular carcinomaAi Shen, Chengyong Tang, Yefei Wang, et al.
Diabetes, Obesity & Metabolism|February 12, 2025
Safety, tolerability, pharmacokinetics and pharmacodynamics of GZR4, a novel once-weekly basal insulin, in healthy participants: A randomized trialChengyong Tang, Rui Su, Lei Wan, et al.
Eclinicalmedicine|May 30, 2023
Artificial intelligence-assisted ultrasound image analysis to discriminate early breast cancer in Chinese population: a retrospective, multicentre, cohort studyJianwei Liao, Yu Gui, Zhilin Li, et al.
Pageof 3